PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Elexacaftor→

Elexacaftor PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
2216712-66-0
Molecular formula
C26H34F3N7O4S
Molecular weight
597.7 g/mol
Drug class
CFTR correctorcomponent of elexacaftor/tezacaftor/ivacaftor combination
Mechanism of action
Binds CFTR at a distinct site from tezacaftor and improves folding, processing and trafficking of F508del-mutant CFTR to the cell surface. It is used with tezacaftor and ivacaftor, which further correct CFTR processing and potentiate channel opening.
Indications / reported uses
  • Component of the fixed triple combination TRIKAFTA/KAFTRIO for treatment of cystic fibrosis in eligible patients with at least one responsive CFTR mutation; not a standalone approved indication

Sources: US DailyMed — TRIKAFTA · EMA EPAR — Kaftrio · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Elexacaftor PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Elexacaftor Permitted Daily Exposure (PDE) report (the Elexacaftor PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Elexacaftor Occupational Exposure Limit (OEL) report (the Elexacaftor OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.